Standard BioTools Inc. (LAB) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Standard BioTools, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead. John Graziano Thank you, operator, and good afternoon, everyone. Welcome to the Standard BioTools first quarter 2025 earnings conference call. Leading the call today is Michael Egholm, President and Chief Executive Officer, and Alex Kim, Chief Financial Officer. At the close of market today, Standard Biotools released its financial results for the quarter ended March 31st, 2025. During this call, we will review our results and provide an update on our financial and operational performance, 2025 outlook, market trends, and strategic initiatives. During the call, we'll make forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our business, our outlook for 2025 and future financial results, market trends and opportunities, the impacts of tariffs and funding pressures, and our expectations related to the combined operations with Somalogic, including potential synergies and our business outlook for the combined company. These statements are subject to substantial risks and uncertainties, that may cause actual events or results to differ materially from current expectations. For informati...